56
Participants
Start Date
November 14, 2012
Primary Completion Date
August 6, 2019
Study Completion Date
August 30, 2022
aflibercept
4 mg/kg as a 1-hour IV(intervenous) infusion
oxaliplatin
85 mg/m2 IV infused over 2 hours
leucovorin
200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin
fluorouracil
400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
Correlative Studies
Patients are required to have tissue available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.
DCE MRI
Images at weeks 0, and after 8 weeks +/- 1 week of treatment (after Cycle 2).
f18FDG-PET
18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG). FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers, including colorectal cancer (99-102).
PET (positron emission tomography)
Correlative studies
Montefiore Medical Center, The Bronx
Roswell Park Cancer Institute, Buffalo
Virginia Commonwealth University, Richmond
University of North Carolina, Chapel Hill
Ohio State University Medical Center, Columbus
University of Michigan, Ann Arbor
Collaborators (1)
Sanofi
INDUSTRY
John Hays
OTHER